InsiderTrades.com logo
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Jeffrey J. Jensen net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jeffrey Jensen Biography and Net Worth

EVP & Chief Clinical Devel. Officer of Inhibrx

Mr. Jensen joined our team in March 2020 and is responsible for the success of our clinical programs through leadership, strategic oversight, and team direction. From 2016 through 2019, he served as Senior VP of Clinical Development at La Jolla Pharmaceutical Co, where he led the clinical and global safety teams, achieving FDA and EMA approval for an investigational synthetic human peptide (Giapreza®).

Mr. Jensen has over 30 years of experience in drug development at biotech and pharmaceutical companies in the U.S. and Europe. Previously, he was Vice President of Clinical Operations and Clinical Lead at Pfizer, leading the development operations team for axitinib (Inlyta®), and held senior positions at several biotech and contract research companies (e.g., Metabasis, Excaliard, Syneos, PPD, Quintiles). He specializes in managing global teams and leading partnerships with research investigators and key opinion leaders. Mr. Jensen received his B.S. in Biochemistry and Biophysics from Oregon State University.

How do I contact Jeffrey J. Jensen?

The corporate mailing address for Mr. Jensen and other Inhibrx executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Jeffrey J. Jensen's contact information.

Has Jeffrey J. Jensen been buying or selling shares of Inhibrx?

Jeffrey J. Jensen has not been actively trading shares of Inhibrx within the last three months. Learn More on Jeffrey J. Jensen's trading history.

Who are Inhibrx's active insiders?

Inhibrx's insider roster includes Brendan Eckelman (Insider), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), and Mark Lappe (Founder). Learn More on Inhibrx's active insiders.

Are insiders buying or selling shares of Inhibrx?

During the last twelve months, Inhibrx insiders bought shares 8 times. They purchased a total of 163,228 shares worth more than $2,627,085.64. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 300,000 shares worth more than $10,290,000.00. The most recent insider tranaction occured on September, 16th when CEO Mark Lappe bought 13,037 shares worth more than $223,323.81. Insiders at Inhibrx own 22.2% of the company. Learn More about insider trades at Inhibrx.

Information on this page was last updated on 9/16/2024.

Jeffrey J. Jensen Insider Trading History at Inhibrx

See Full Table

Jeffrey J. Jensen Buying and Selling Activity at Inhibrx

This chart shows Mr. Jeffrey J. Jensen's buying and selling at Inhibrx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inhibrx Company Overview

Inhibrx logo
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $13.83
Low: $12.25
High: $14.77

50 Day Range

MA: $15.75
Low: $13.83
High: $17.49

2 Week Range

Now: $13.83
Low: $10.80
High: $18.95

Volume

178,264 shs

Average Volume

51,015 shs

Market Capitalization

$200.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.